Lamotrigine add-on therapy to venlafaxine treatment in adolescent-onset bipolar II disorder: a case report covering an 8-month observation period

Basit Öğe Kaydı
dc.contributor.authorBildik, T.
dc.contributor.authorTamar, M.
dc.contributor.authorKorkmaz, S.
dc.contributor.authorGokcen, S.
dc.contributor.authorOzbaran, B.
dc.contributor.authorErermis, S.
dc.contributor.authorAydin, C.
dc.date.accessioned2019-10-27T19:18:48Z
dc.date.available2019-10-27T19:18:48Z
dc.date.issued2006
dc.departmentEge Üniversitesien_US
dc.description.abstractObservations made with lamotrigine add-on therapy with venlafaxine in this case give clues for some aspects of its use in adolescent-onset bipolar 11 disorder. An 18-year-old adolescent boy with a 3-year history of bipolar 11 disorder had experienced 2 episodes of hypomania and 4 episodes of major depression. He had been depressed for the last 3 months and had taken olanzapine 5 mg daily for over 6 weeks as mood stabilizer but was still depressed at referral. Other aspects of the patient history included anhedonia, psychomotor retardation, poor concentration, a feeling of hopelessness, hypersonmia, overeating, weight gain, low energy and a refusal to attend school. Parents reported that his symptoms had recently become more severe. His medicine was replaced by venlafaxine, which has a more rapid onset of action and is often used in bipolar depression, especially in patients with atypical depression. Since the clinical response at 6 weeks was only partial, lamotrigine was added to this regimen. The patient responded to lamotrigine after 3 weeks of treatment while on a dose of 50 mg/day. After 6 weeks of treatment, whilst on a dose of 75 mg/day, his symptoms remitted completely with no evidence of any adverse effects. At the time of publication of this article, the patient had remained euthymic for a total of 8 months. The present report shows that lamotrigine add-on therapy with venlafaxine facilitated clinical remission and that this combination is well tolerated.en_US
dc.identifier.endpage206en_US
dc.identifier.issn0946-1965
dc.identifier.issue5en_US
dc.identifier.pmid16724574en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage198en_US
dc.identifier.urihttps://hdl.handle.net/11454/38645
dc.identifier.volume44en_US
dc.identifier.wosWOS:000237829200002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherDustri-Verlag Dr Karl Feistleen_US
dc.relation.ispartofInternational Journal of Clinical Pharmacology and Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectlamotrigineen_US
dc.subjectbipolar II disorderen_US
dc.subjectadolescenten_US
dc.subjectvenlafaxineen_US
dc.titleLamotrigine add-on therapy to venlafaxine treatment in adolescent-onset bipolar II disorder: a case report covering an 8-month observation perioden_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu